Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fresenius Medical Care AG (FMCQF) Restructuring Costs (2017 - 2025)

Historic Restructuring Costs for Fresenius Medical Care AG (FMCQF) over the last 10 years, with Q1 2025 value amounting to $85.2 million.

  • Fresenius Medical Care AG's Restructuring Costs rose 46020.95% to $85.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $170.6 million, marking a year-over-year increase of 11442.91%. This contributed to the annual value of $60.9 million for FY2024, which is 18449.39% up from last year.
  • Fresenius Medical Care AG's Restructuring Costs amounted to $85.2 million in Q1 2025, which was up 46020.95% from $60.9 million recorded in Q4 2024.
  • Fresenius Medical Care AG's 5-year Restructuring Costs high stood at $85.2 million for Q1 2025, and its period low was -$595.8 million during Q4 2022.
  • In the last 5 years, Fresenius Medical Care AG's Restructuring Costs had a median value of $466106.3 in 2024 and averaged -$126.5 million.
  • In the last 5 years, Fresenius Medical Care AG's Restructuring Costs crashed by 1249.22% in 2022 and then soared by 46020.95% in 2025.
  • Over the past 5 years, Fresenius Medical Care AG's Restructuring Costs (Quarter) stood at -$529.7 million in 2021, then fell by 12.49% to -$595.8 million in 2022, then soared by 87.9% to -$72.1 million in 2023, then skyrocketed by 184.49% to $60.9 million in 2024, then surged by 39.88% to $85.2 million in 2025.
  • Its Restructuring Costs stands at $85.2 million for Q1 2025, versus $60.9 million for Q4 2024 and -$14.3 million for Q3 2024.